Kageshita T, Kawakami Y, Hirai S, Ono T
Department of Dermatology, Kumamoto University School of Medicine, Japan.
J Immunother. 1997 Nov;20(6):460-5. doi: 10.1097/00002371-199711000-00005.
Twenty-eight primary and 29 metastatic melanoma lesions and 18 pigmented nevi lesions were analyzed by using the immunoperoxidase reaction with anti-MART-1 and anti-gp100 monoclonal antibodies (mAbs). The MART-1 was expressed in 28, 29, and 18, and gp100 was expressed in 27, 28, and eight of these lesions, respectively. Intensity and percentage of stained cells with anti-MART-1 mAb were stronger and higher than those with anti-gp100 mAb. MART-1 was expressed homogeneously in primary melanoma and pigmented nevi, whereas it was heterogeneously expressed in metastatic melanoma lesions. The level of expression of MART-1 in primary melanoma lesions did not correlate with any clinicopathologic parameters. These results suggest that anti-MART-1 mAb is a useful tool for immunohistochemical analysis of melanocytic lesions and also is useful for patients' selection and monitoring of antigen-loss variants in clinical trials with the MART-1-based immunotherapy.
采用抗MART-1和抗gp100单克隆抗体（mAb）的免疫过氧化物酶反应，对28个原发性黑色素瘤病灶、29个转移性黑色素瘤病灶以及18个色素痣病灶进行了分析。在这些病灶中，MART-1分别在28个、29个和18个病灶中表达，gp100分别在27个、28个和8个病灶中表达。抗MART-1 mAb染色细胞的强度和百分比高于抗gp100 mAb。MART-1在原发性黑色素瘤和色素痣中呈均匀表达，而在转移性黑色素瘤病灶中呈异质性表达。原发性黑色素瘤病灶中MART-1的表达水平与任何临床病理参数均无相关性。这些结果表明，抗MART-1 mAb是黑色素细胞性病灶免疫组化分析的有用工具，在基于MART-1的免疫治疗临床试验中，也有助于患者的选择以及对抗抗原丢失变异体的监测。
